LifeMD review
Each published figure is medication only, with a $149 monthly program fee charged alongside it.
The verdict
LifeMD publishes $199 for the Wegovy pen, $149 for the Wegovy pill and $299 for the Zepbound vial, and every one of those is described as medication only. A $149 monthly program fee is charged alongside. The pages also state the medication can fall to $0 to $25 a month with insurance.
Disclosure: This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
- Category
- GLP-1 telehealth
- Molecule
- Semaglutide · Tirzepatide
- Form
- Injection · Oral
- States
- 50
- Injection
- From $348/mo
- Oral
- From $298/mo
- Prescription
- Required
- Compounded
- No
- Availability
- 50 states
LifeMD is a telehealth practice covering a stated fifty states, selling FDA-approved brand semaglutide and tirzepatide across injected and oral forms. What separates its pricing from most here is that the medication and the service are quoted as separate lines rather than as one figure, and both are published.
Who writes the prescription, and what do they see?
The program fee buys the clinical relationship, and LifeMD prices it openly rather than folding it into a headline. That makes the service cost visible in a way a bundled figure never is. What the fee covers in practice — how often a prescriber is seen, what is reviewed — the pages do not describe.
Two charges, both disclosed, is a more honest structure than one charge that hides the other. The consequence is that no published figure here is what a buyer pays. The semaglutide injection at $199 is $348 a month once the program fee is counted, and the oral at $149 is $298.
What happens when the dose goes up?
Nothing is published about what the medication charge does as the dose rises. The program fee is stated as a flat monthly amount, so at least one half of the bill is known to hold. On the medication half a reader has only the entry figure.
What the price includes
Read both lines together. Six months on the semaglutide injection is $2,088 with the fee included, against $1,194 if the fee is ignored — which is why it cannot be. The insurance path changes the arithmetic most. LifeMD states the medication can reach $0 to $25 a month for a buyer whose plan covers it. The program fee then becomes the dominant cost rather than a surcharge.
Where it holds up, and where it does not
- Strength: Medication and service priced separately
- Strength: The program fee amount is published
- Strength: An insurance path is priced, not just implied
- Strength: Coverage stated across fifty states
- Limitation: No published figure is the full cost
- Limitation: The fee exceeds one medication line
- Limitation: Dose behavior is not published
- Limitation: Which route a buyer lands on is unstated
What the evidence says about this kind of treatment
The assessment above is about LifeMD. These are about the drugs it sells, and they are traced to the primary literature.
- Right for
- A reader with insurance that may cover the medication, leaving the fee as the main cost.
- Wrong for
- A reader comparing medication headlines across sellers without adding a standing fee.
The evidence behind what LifeMD prescribes
These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation.
- Cochrane Review of Semaglutide for Obesity: 18 Trials Graded
A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower.
- Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?
In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points.
How LifeMD compares
| Seller | Who it suits | Go |
|---|---|---|
 NextMeds | A reader who wants one charge covering medication and care, at a rate stated to hold from the first order. | See NextMeds → |
 Alloy | A reader comparing three molecules at one seller, where the same fixed fee sits on top of each of them. | See Alloy → |
| EverSlim | A reader who wants one monthly charge covering the medication, the visit and the postage, without a prepay term attached to reach the rate. | See EverSlim → |
More GLP-1 telehealth sellers reviews: Society of YouSomi HealthSomira HealthSouthern Vitality and Weight LossSpryStackMD
Sponsored alternative
SkinnyRx
Readers choosing tirzepatide, the one line with a published standing rate
Check SkinnyRx availability →Frequently asked
- What does LifeMD actually cost?
- The medication figure plus $149 a month. The semaglutide injection at $199 becomes $348, and the oral at $149 becomes $298.
- Can the medication really be $0?
- LifeMD states it can fall to $0 to $25 a month with insurance. The program fee still applies, so it becomes the main charge rather than a surcharge.
- Is the program fee avoidable?
- Nothing on the pages suggests it is. Every medication figure is described as medication only, with the fee charged alongside.
- Is LifeMD legit?
- LifeMD is a GLP-1 telehealth sellers service. Its stated availability: 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay.
- Is LifeMD expensive compared with other GLP-1 telehealth sellers?
- LifeMD publishes a starting figure of $298/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts LifeMD above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes.